Video
Dr. Usmani on Ibrutinib/Carfilzomib in Patients With Multiple Myeloma
Author(s):
Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.
Patients who were eligible to receive the combination were pretreated with bortezomib and an immunomodulatory agent, Usmani explains. The median prior lines of therapy was three; 25% of patients had previous exposure to carfilzomib and pomalidomide.
The highest dose of ibrutinib administered to patients was 560 mg, while the highest dose of carfilzomib was 227 mg. In the combination arm, the overall response rate was approximately 58% and the clinical benefit rate was 67%. No significant toxicities were seen with the combination, Usmani adds. Next steps include a dose expansion as well as a phase III study.
<<<
